Judges at this year’s International Pharmaceutical Expo 2017 (INTERPHEX) have hailed Watson-Marlow Fluid Technology Group’s Quantum peristaltic pump as ‘cutting-edge’.
As winner of the Best Technological Innovation category, the Quantum peristaltic pump with patented ReNu SU Technology cartridge has been recognised as: ‘a technology with the potential to change the way pharmaceutical and biotech companies operate.’
Launched at INTERPHEX in March, Quantum offers a step change in pump technology for bioprocessing, enabling higher downstream process yields throughout the pressure range and exceeding the performance of any other pump available. Its patented single-use technology provides exceptional downstream process performance, delivering higher yields and improved flow linearity throughout the 3 bar pressure range. Quantum outperforms any other bioprocessing pump available, with ultra-low shear and a class leading 4000:1 turn down ratio
Commenting on the award win, Steve Lavargna, Sales and Marketing Director at Watson-Marlow Fluid Technology Group comments:
“When we designed Quantum, we wanted to redefine peristaltic pump performance for single-use downstream bioprocessing. We are very confident that this has been achieved. However, to have achieved external recognition from respected industry peers and experts is fantastic news on two levels. Firstly, it is well deserved by Quantum’s product development team – all of whom have worked so hard. Secondly, from a customer perspective, the award offers an additional layer of market confidence and advocacy in our leading-edge technology.”
Company name: Watson-Marlow Fluid Technology Group
Website: www.wmftg.com
E-mail: info@wmftg.co.uk
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.